Erlina 25mg/5mg Tablets (30s)

Description

Erlina 25 mg/5 mg is a prescription combination tablet used to help control blood glucose in adults with type 2 diabetes mellitus. It combines empagliflozin with linagliptin and should be used with diet, exercise, and medical supervision.

• Manufacturer Name: Pharmevo
• Drug Class: Sodium-glucose cotransporter-2 (SGLT2) inhibitor + dipeptidyl peptidase-4 (DPP-4) inhibitor
• Dosage Form: Tablet
• Storage: Store at room temperature below 30°C in the original packaging, protected from moisture and excessive heat. Keep out of the reach of children.
• Pack Size: Pack of 30 Tablets

Erlina 25mg/5mg Tablets (30s) Available Online in Pakistan

Dwatson offers Erlina 25mg/5mg Tablets (30s) at Rs. 2124.6, with fast, discreet delivery across Pakistan.

Ingredients

• Empagliflozin 25 mg
• Linagliptin 5 mg

Benefits

• Improves blood glucose control in adults with type 2 diabetes mellitus.
• Used together with diet and exercise.
• May be prescribed alone or with other diabetes medicines when additional glucose control is required.
• Not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.

Usage & Safety

For Adult

• Take one tablet once daily, or use exactly as prescribed by the physician.
• Swallow whole with water; it may be taken with or without food.
• Maintain adequate fluid intake unless fluid restriction has been advised.
• Dosage may require adjustment or discontinuation during acute illness, dehydration, surgery, or significant kidney impairment.

For Children

• Safety and effectiveness for children and adolescents under 18 years have not been established for this fixed-dose combination.
• Not routinely recommended for pediatric use unless specifically prescribed by a specialist.
• Do not use in children or adolescents with type 1 diabetes or suspected diabetic ketoacidosis.

Side Effects

• Common effects may include increased urination, thirst, genital fungal infections, urinary tract infections, nausea, or nasopharyngitis.
• Low blood sugar is more likely when used with insulin or sulfonylureas.
• Seek urgent medical attention for symptoms of ketoacidosis such as nausea, vomiting, abdominal pain, unusual tiredness, breathing difficulty, or confusion, even if blood glucose is not very high.
• Seek medical attention for severe allergic reactions, facial or throat swelling, severe rash, or difficulty breathing.
• Rare but serious effects may include severe dehydration, kidney problems, pancreatitis, or serious genital or perineal infection.

Contraindications

• Do not use in patients with a known allergy to empagliflozin, linagliptin, or any tablet ingredient.
• Contraindicated in diabetic ketoacidosis or acute metabolic decompensation of diabetes.
• Not indicated for type 1 diabetes mellitus.
• Avoid or use only under specialist supervision in severe kidney disease, dialysis, marked dehydration, or recurrent urinary or genital infections.
• Use caution in patients with a history of pancreatitis, low blood pressure, heart failure, or conditions causing fluid loss.

Precautions & Warnings

• Insulin and sulfonylureas may increase the risk of hypoglycemia; the prescriber may need to reduce their dose.
• Diuretics and other medicines that lower blood pressure may increase dehydration, dizziness, or low blood pressure.
• Strong enzyme inducers such as rifampicin, carbamazepine, phenytoin, or phenobarbital may reduce linagliptin effectiveness.
• Tell the physician about all diabetes medicines, kidney-affecting medicines, lithium, diuretics, and blood-pressure medicines.
• Alcohol may increase dehydration and may contribute to poor diabetes control; avoid excessive alcohol intake.

Pregnancy

• Use during pregnancy only when specifically prescribed; empagliflozin is generally avoided, particularly during the second and third trimesters.
• Inform the physician immediately if pregnancy occurs or is planned.
• Breastfeeding is generally not recommended during treatment because potential effects on the nursing infant cannot be excluded.